Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ab - lansoprazol - munsönderfallande tablett - 15 mg - aspartam hjälpämne; sockersfärer hjälpämne; lansoprazol 15 mg aktiv substans; mannitol hjälpämne; natriumlaurilsulfat hjälpämne - lansoprazol

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ab - klozapin - tablett - 100 mg - laktosmonohydrat hjälpämne; klozapin 100 mg aktiv substans

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ab - klozapin - tablett - 25 mg - laktosmonohydrat hjälpämne; klozapin 25 mg aktiv substans

Uni Eropa - Swedia - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastiska medel - behandling av bröstcancer, speciella former av lungcancer (icke-småcellig lungcancer), prostatacancer, magcancer eller huvud och nackcancer.

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ab - montelukastnatrium - tuggtablett - 5 mg - montelukastnatrium 5,19 mg aktiv substans; aspartam hjälpämne; natriumlaurilsulfat hjälpämne; mannitol hjälpämne - montelukast

Uni Eropa - Swedia - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ab - lansoprazol - munsönderfallande tablett - 30 mg - mannitol hjälpämne; natriumlaurilsulfat hjälpämne; lansoprazol 30 mg aktiv substans; aspartam hjälpämne; sockersfärer hjälpämne - lansoprazol

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ire healthcare ltd - linezolid - infusionsvätska, lösning - 2 mg/ml - glukosmonohydrat hjälpämne; linezolid 2 mg aktiv substans

Uni Eropa - Swedia - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - insulin aspart - diabetes mellitus - läkemedel som används vid diabetes - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Swedia - Swedia - Läkemedelsverket (Medical Products Agency)

mylan ab - imatinibmesilat - filmdragerad tablett - 100 mg - imatinibmesilat 119,5 mg aktiv substans - imatinib